BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 19693501)

  • 1. Toxic epidermal necrolysis following thalidomide and dexamethasone treatment for multiple myeloma: a case report.
    Eo WK; Kim SH; Cheon SH; Lee SH; Jeong JS; Kim YS; Chang HK; Suh KS; Kim HY
    Ann Hematol; 2010 Apr; 89(4):421-2. PubMed ID: 19693501
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumor lysis syndrome following thalidomide and dexamethasone therapy for newly diagnosed multiple myeloma.
    Huston A; Brown J; Roodman GD
    Exp Hematol; 2006 Dec; 34(12):1616. PubMed ID: 17157156
    [No Abstract]   [Full Text] [Related]  

  • 3. Lenalidomide and its role in the management of multiple myeloma.
    Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma.
    Rajkumar SV; Gertz MA; Witzig TE
    N Engl J Med; 2000 Sep; 343(13):972-3. PubMed ID: 11012329
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of thalidomide in multiple myeloma.
    Schwab C; Jagannath S
    Clin Lymphoma Myeloma; 2006 Jul; 7(1):26-9. PubMed ID: 16879766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxic epidermal necrolysis induced by thalidomide and dexamethasone treatment for multiple myeloma.
    Hwang S; Woo Y; Kim M; Park HJ
    Int J Dermatol; 2017 Feb; 56(2):e35-e37. PubMed ID: 27805271
    [No Abstract]   [Full Text] [Related]  

  • 7. Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome.
    Chim CS
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):181-2. PubMed ID: 17846773
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and efficacy of a combination therapy with Revlimid, Adriamycin and dexamethasone (RAD) in relapsed/refractory multiple myeloma (MM): a single-centre experience.
    Caravita T; Siniscalchi A; Tendas A; Cupelli L; Ales M; Perrotti A; Niscola P; de Fabritiis P
    Ann Hematol; 2011 Jan; 90(1):115-6. PubMed ID: 20422414
    [No Abstract]   [Full Text] [Related]  

  • 9. Thalidomide and dexamethasone: therapy for multiple myeloma.
    Kumar S; Rajkumar SV
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):759-66. PubMed ID: 16221046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
    Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z
    Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma.
    Morris TC; Kettle PJ; Drake M; Jones FC; Hull DR; Boyd K; Morrison A; Clarke P; O'Reilly P; Quinn J
    Br J Haematol; 2008 Nov; 143(3):349-54. PubMed ID: 18759764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatal sepsis after thalidomide/dexamethasone treatment in two patients with multiple myeloma.
    Wölfler A; Bauer F; Zollner G; Weber K; Sill H; Linkesch W
    Haematologica; 2003 Apr; 88(4):ELT12. PubMed ID: 12681989
    [No Abstract]   [Full Text] [Related]  

  • 14. [Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%].
    Wu KL; Schaafsma MR; Lokhorst HM; Wijermans PW; van der Holt B; Sonneveld P
    Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1445-8. PubMed ID: 12190011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of multiple myeloma with elotuzumab plus pomalidomide and dexamethasone].
    Rasche L; Einsele H; Nitschmann S
    Internist (Berl); 2019 Jun; 60(6):658-660. PubMed ID: 30941437
    [No Abstract]   [Full Text] [Related]  

  • 16. Severe epidermal necrolysis after bortezomib treatment for multiple myeloma.
    Fang B; Song Y; Ma J; Zhao RC
    Acta Haematol; 2007; 118(2):65-7. PubMed ID: 17505132
    [No Abstract]   [Full Text] [Related]  

  • 17. Thalidomide in the treatment of multiple myeloma.
    Kastritis E; Dimopoulos MA
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):681-99. PubMed ID: 18070713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates may potentiate effects of thalidomide-dexamethasone combination in advanced multiple myeloma.
    Ural AU; Avcu F
    Am J Hematol; 2006 May; 81(5):385-6; author reply 386. PubMed ID: 16628715
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
    Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
    Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
    Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
    Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.